Cervical cancer immunotherapy: facts and hopes

L Ferrall, KY Lin, RBS Roden, CF Hung, TC Wu - Clinical Cancer Research, 2021 - AACR
It is a sad fact that despite being almost completely preventable through human
papillomavirus (HPV) vaccination and screening, cervical cancer remains the fourth most …

The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?

C Patel, JML Brotherton, A Pillsbury… - …, 2018 - eurosurveillance.org
Background: A National human papilloma virus (HPV) Vaccination Programme for the
prevention of HPV infection and associated disease using the quadrivalent HPV vaccine …

Perspectives for therapeutic HPV vaccine development

A Yang, E Farmer, TC Wu, CF Hung - Journal of biomedical science, 2016 - Springer
Background Human papillomavirus (HPV) infections and associated diseases remain a
serious burden worldwide. It is now clear that HPV serves as the etiological factor and …

Hallmarks of HPV carcinogenesis: The role of E6, E7 and E5 oncoproteins in cellular malignancy

D Estêvão, NR Costa, RMG da Costa… - Biochimica et Biophysica …, 2019 - Elsevier
Human papillomavirus (HPV) is the most common sexually transmitted infectious agent
worldwide, being also responsible for 5% of all human cancers. The integration and …

Immunotherapy in ovarian, endometrial and cervical cancer: state of the art and future perspectives

J Ventriglia, I Paciolla, C Pisano, SC Cecere… - Cancer treatment …, 2017 - Elsevier
The tumors of the female genital tract represent a leading cause of morbidity and mortality
among women worldwide. Substantial progresses have been made in ovarian cancer, with …

[PDF][PDF] Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research

SJ Lee, A Yang, TC Wu… - Journal of gynecologic …, 2016 - synapse.koreamed.org
Cervical cancer is the fourth most lethal women's cancer worldwide. Current treatments
against cervical cancer include surgery, radiotherapy, chemotherapy, and anti-angiogenic …

The human papillomavirus E6 PDZ binding motif: from life cycle to malignancy

K Ganti, J Broniarczyk, W Manoubi, P Massimi, S Mittal… - Viruses, 2015 - mdpi.com
Cancer-causing HPV E6 oncoproteins are characterized by the presence of a PDZ binding
motif (PBM) at their extreme carboxy terminus. It was long thought that this region of E6 had …

Current state in the development of candidate therapeutic HPV vaccines

A Yang, J Jeang, K Cheng, T Cheng… - Expert review of …, 2016 - Taylor & Francis
The identification of human papillomavirus (HPV) as an etiological factor for HPV-associated
malignancies creates the opportunity to control these cancers through vaccination …

British HIV Association guidelines on the use of vaccines in HIV-positive adults 2015

AM Geretti, G Brook, C Cameron, D Chadwick… - HIV …, 2016 - discovery.ucl.ac.uk
These guidelines provide updated, GRADE-based recommendations on the use of vaccines
in HIVpositive adults. Several factors have made the updating of HIV-specific vaccination …

Special issue about head and neck cancers: HPV positive cancers

P Economopoulou, I Kotsantis, A Psyrri - International journal of molecular …, 2020 - mdpi.com
The oropharynx has become the leading primary site for Human Papilloma Virus (HPV)-
associated head and neck cancer. HPV positive oropharyngeal squamous cell carcinoma …